6,678 trials
Keratitis
Primary: Number of Participants Who Improved on the Impact of Dry Eye on Everyday Life (IDEEL) Scale [Using the Symptom Bother Module at Week 12] — 17 Participants
Diabetes Mellitus, Type 2
Primary: Number of Neonates With Composite Adverse Neonatal Outcome — 31; 35 Participants
Age Related Macular Degeneration · Polypoidal Choroidal Vasculopathy
Primary: Mean Change in Best Corrected Visual Acuity (BCVA) — 8.1; 7.9 ETDRS Letters
Diabetes Mellitus, Type 1
Primary: Percentage of Time in Range: Sensor Glucose Values Between 70-180 mg/dl — 78.4; 75.3 percentage of time — p=0.051
Arthritis, Rheumatoid
Primary: Incidence Rate of Adjudicated Malignancies Excluding Non-melanoma Skin Cancers (NMSC) — 1.13; 1.13; 1.13; 0.77 participants with event/100 PY
Parkinsons Disease
Primary: Change in the Mean Daily Overactive Bladder-Symptom Composite Score. — -3.2; -8.9 units on a scale
Generalized Pustular Psoriasis · Erythrodermic Psoriasis
Primary: Maintenance Dosing Period: Number of Participants Who Improved Global Improvement Score (GIS) at Least 1 Point From Week 12 Through Week 20 and With ≤2 of GIS — 1; 0…
Hepatitis C, Chronic · HIV Infection
Primary: Rates of Grade 2 and Higher Alanine Aminotransferase (ALT) Elevations — 24; 30 Participants
Liver Diseases · Portal Hypertension
Primary: Diagnostic Accuracy of SHAPE Liver Pressure Estimates (in dB) for Diagnosing Portal Hypertension With Catheter Pressure Measurements (in mmHg) as the Reference Standard…
Healthy
Primary: Change in Brain Nicotinamide Adenine Dinucleotide Metabolites NAD+/NADH — -0.79 ratio
Chronic Obstructive Pulmonary Disease
Primary: Total COPD Exacerbation Rate — 1.00; 0.86; 0.89 Exacerbations per participant year
HIV Positive · Malnourished
Primary: Grade 3 or Higher Adverse Events Through 24 Weeks — 13; 10 Participants — p=0.40
Osteoarthritis, Knee
Primary: Total Blood Loss After Operation — 678; 733 ml — p=0.276
Pain, Postoperative · Opioid Use
Primary: Pain With Physical Therapy on Post-operative Day 1 — 3.6; 3.9 score on a scale
Migraine
Primary: Proportion of Patients With Treatment Discontinuation Due to an Adverse Event (AE) During the Double-blind Treatment Epoch/Period (DBTE) — 41; 151 Participants — p=<.001